Chrissy Teigen ‘Shocked, In Deep Pain’ After Pregnancy Loss, Shares Son’s Name


  • Chrissy Teigen lost her baby after being hospitalized due to pregnancy complications
  • Teigen didn’t expect to conceive naturally
  • John Legend’s wife shared last month that she had really bad pregnancy headaches

Chrissy Teigen is shocked and in deep pain after losing her baby days after she was admitted to the hospital due to pregnancy complications. The grieving celebrity mom took to social media to relay the sad news to her followers, who were also waiting for the arrival of her baby.

“We are shocked and in the kind of deep pain you only hear about, the kind of pain we’ve never felt before,” she wrote on Instagram.

“We were never able to stop the bleeding and give our baby the fluids he needed, despite bags and bags of blood transfusions. It just wasn’t enough.”

Teigen added that she and husband John Legend don’t usually decide on baby names

Read More

PRA Health (PRAH) Enters Into Strategic Deal With Deep Lens

PRA Health Sciences, Inc. PRAH recently inked a strategic deal with Deep Lens, Inc. to expedite patient access and recruitment for oncology clinical trials. This deal will combine best-in-class technologies that can boost identification, screening and matching of cancer patients to precision-based clinical oncology trials globally. Interestingly, this combined solution has been deployed to Microsoft Azure.

Notably, this deal is likely to boost PRA Health’s Clinical Research segment, which covers a broad array of services across the spectrum of clinical development programs.

VIPER Patient Screening Platform at a Glance

Deep Lens’ breakthrough VIPER patient screening platform is deployed by cancer centers, integrated delivery networks, and community oncology networks to detect and match oncology patients to life saving clinical trials and best precision therapies.

Post qualification for trials, the VIPER system will refer these patients to PRA Health’s industry leading Mobile Health Platform that has also been deployed on Azure. This,

Read More

Neoadjuvant IO Yields Deep Responses in Head and Neck Cancer

Preoperative checkpoint inhibition led to deep responses in select patients with head and neck squamous cell carcinoma (SCC) with mostly human papillomavirus (HPV)-negative disease, a small, single-arm study found.

Among 29 evaluable patients included in the IMCISION trial, 31% achieved a near pathologic complete response (pCR) when treated with two courses of anti-PD-1 nivolumab (Opdivo) with or without ipilimumab (Yervoy), a CTLA-4-directed immune checkpoint inhibitor, reported Lotje Zuur, MD, PhD, of the Netherlands Cancer Institute in Amsterdam.

Patients achieving near pCR, defined as primary tumor shrinkage of at least 90%, had a 14-month recurrence-free survival (RFS) rate of 100%, she said at the 2020 European Society for Medical Oncology (ESMO) virtual congress.

This survival benefit was significantly greater than patients with lesser responses in the study, which included another 31% of patients with responses ranging from 20% to 89%, as well as a historical cohort of more than 100 patients

Read More